Wedbush Issues Negative Estimate for Scholar Rock Earnings

Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) - Equities researchers at Wedbush cut their Q2 2025 earnings per share (EPS) estimates for Scholar Rock in a report issued on Wednesday, May 14th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.66) per share for the quarter, down from their prior forecast of ($0.61). Wedbush currently has a "Outperform" rating and a $50.00 target price on the stock. The consensus estimate for Scholar Rock's current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Scholar Rock's Q3 2025 earnings at ($0.64) EPS, Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.61) EPS, Q1 2026 earnings at ($0.63) EPS, Q2 2026 earnings at ($0.58) EPS, Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($2.04) EPS, FY2027 earnings at ($0.58) EPS and FY2028 earnings at $0.49 EPS.

Scholar Rock Price Performance

SRRK traded down $0.46 on Monday, reaching $30.00. 825,200 shares of the company's stock were exchanged, compared to its average volume of 1,267,164. The stock has a market cap of $2.85 billion, a PE ratio of -12.77 and a beta of 0.37. The stock's fifty day moving average price is $30.77 and its 200-day moving average price is $35.94. Scholar Rock has a twelve month low of $6.76 and a twelve month high of $46.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period in the prior year, the business earned ($0.59) EPS.

Insider Transactions at Scholar Rock

In other Scholar Rock news, insider Tracey Sacco sold 5,000 shares of the business's stock in a transaction on Friday, April 25th. The stock was sold at an average price of $32.83, for a total transaction of $164,150.00. Following the transaction, the insider now owns 71,750 shares of the company's stock, valued at approximately $2,355,552.50. The trade was a 6.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Katie Peng sold 1,006 shares of the business's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $34.42, for a total value of $34,626.52. Following the transaction, the director now directly owns 30,319 shares in the company, valued at $1,043,579.98. This trade represents a 3.21% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 154,798 shares of company stock worth $5,482,238 in the last ninety days. Insiders own 13.30% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in Scholar Rock by 17.6% in the 4th quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company's stock valued at $205,013,000 after purchasing an additional 708,817 shares during the last quarter. Principal Financial Group Inc. acquired a new position in Scholar Rock in the fourth quarter valued at approximately $274,000. Blackstone Inc. acquired a new position in Scholar Rock in the fourth quarter valued at approximately $910,000. Rhumbline Advisers lifted its holdings in Scholar Rock by 13.2% in the fourth quarter. Rhumbline Advisers now owns 113,261 shares of the company's stock valued at $4,895,000 after acquiring an additional 13,247 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Scholar Rock in the fourth quarter valued at approximately $2,625,000. Institutional investors and hedge funds own 91.08% of the company's stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.